Serum HIF-1α and VEGF Levels Pre- and Post-TACE in Patients with Primary Liver Cancer

doi:10.1016/S1001-9294(11)60041-2

摘要/Abstract

摘要： Objective To investigate the expression levels of serum hypoxia inducible factor 1 alpha (HIF-1α) and vascular endothelial growth factor (VEGF) pre- and post-transcatheter arterial chemoembolization (TACE) in patients with primary liver cancer (PLC), and correlations between prognosis factors and serum HIF-1α as well as VEGF levels.
Methods Forty consecutive patients fulfilling diagnostic criteria for PLC undergoing TACE from March 2008 to May 2009 were enrolled into the study. The serum HIF-1α and VEGF levels of PLC patients pre- and 1 day, 1 week, 1 month post-TACE were analyzed using ELISA, and compared with that of 20 healthy volunteers. Patients were divided into complete response (CR) and partial response (PR), stable disease (SD), progressive disease (PD) groups according to the therapeutic efficacy. Pearson correlation was used to analyze the correlation between different clinical variables and serum HIF-1α and VEGF levels before TACE, and correlation between serum HIF-1α and VEGF levels was also evaluated.
Results The expression levels of serum HIF-1α and VEGF in PLC patients were 154.94±83.29 and 264.00±148.10 pg/mL pre-TACE, and both of them were significantly higher than those in control group (23.84±8.15 and 69.78±21.42 pg/mL, all P<0.01). One day after TACE, both serum HIF-1α (570.64± 230.87 pg/mL) and VEGF levels (362.07±102.25 pg/mL) reached the peak values (all P<0.01). One week post-TACE, expression levels of them were decreased (198.62±92.11 and 283.52±145.46 pg/mL respectively), but still significantly higher than those before TACE (all P<0.01). The levels of both HIF-1α (133.96±57.02 vs. 255.74±123.44 pg/mL) and VEGF (150.96±84.89 vs. 368.95±161.90 pg/mL) in CR group 1 month post-TACE were significantly lower than those in PR+SD+PD group (all P<0.01). The level of serum HIF-1α was positively correlated with serum VEGF level (r=0.42, P<0.001). Both serum HIF-1α and VEGF levels were observed to be correlated with portal vein tumor thrombi (P<0.05) and metastasis (P<0.05).
Conclusion The HIF-1α and VEGF might play an important role in relapse of PLC. They might be considered as predictors of the efficacy of TACE and metastasis of PLC.

关键词: liver neoplasms, transcatheter arterial chemoembolization, hypoxia inducible factor 1 alpha, vascular endothelial growth factor

Abstract: Objective To investigate the expression levels of serum hypoxia inducible factor 1 alpha (HIF-1α) and vascular endothelial growth factor (VEGF) pre- and post-transcatheter arterial chemoembolization (TACE) in patients with primary liver cancer (PLC), and correlations between prognosis factors and serum HIF-1α as well as VEGF levels.
Methods Forty consecutive patients fulfilling diagnostic criteria for PLC undergoing TACE from March 2008 to May 2009 were enrolled into the study. The serum HIF-1α and VEGF levels of PLC patients pre- and 1 day, 1 week, 1 month post-TACE were analyzed using ELISA, and compared with that of 20 healthy volunteers. Patients were divided into complete response (CR) and partial response (PR), stable disease (SD), progressive disease (PD) groups according to the therapeutic efficacy. Pearson correlation was used to analyze the correlation between different clinical variables and serum HIF-1α and VEGF levels before TACE, and correlation between serum HIF-1α and VEGF levels was also evaluated.
Results The expression levels of serum HIF-1α and VEGF in PLC patients were 154.94±83.29 and 264.00±148.10 pg/mL pre-TACE, and both of them were significantly higher than those in control group (23.84±8.15 and 69.78±21.42 pg/mL, all P<0.01). One day after TACE, both serum HIF-1α (570.64± 230.87 pg/mL) and VEGF levels (362.07±102.25 pg/mL) reached the peak values (all P<0.01). One week post-TACE, expression levels of them were decreased (198.62±92.11 and 283.52±145.46 pg/mL respectively), but still significantly higher than those before TACE (all P<0.01). The levels of both HIF-1α (133.96±57.02 vs. 255.74±123.44 pg/mL) and VEGF (150.96±84.89 vs. 368.95±161.90 pg/mL) in CR group 1 month post-TACE were significantly lower than those in PR+SD+PD group (all P<0.01). The level of serum HIF-1α was positively correlated with serum VEGF level (r=0.42, P<0.001). Both serum HIF-1α and VEGF levels were observed to be correlated with portal vein tumor thrombi (P<0.05) and metastasis (P<0.05).
Conclusion The HIF-1α and VEGF might play an important role in relapse of PLC. They might be considered as predictors of the efficacy of TACE and metastasis of PLC.

Key words: liver neoplasms, transcatheter arterial chemoembolization, hypoxia inducible factor 1 alpha, vascular endothelial growth factor

Zhong-zhi Jia, Guo-min Jiang, Yao-liang Feng. Serum HIF-1α and VEGF Levels Pre- and Post-TACE in Patients with Primary Liver Cancer[J].Chinese Medical Sciences Journal, 2011, 26(3): 158-162.

参考文献 16

1.	Parkin DM, Bray F, Ferlay J, et al. Global cancer statistics, 2002. CA Cancer J Clin 2005; 55:74-108.
2.	McGlynn KA, London WT. Epidemiology and natural his-tory of hepatocellular carcinoma. Best Pract Res Clin Gastroenterol 2005; 19:3-23.
3.	Cai J, Hu J, Che X, et al. Prognosis of primary liver car-cinoma treated with local resection. Chin Med J (Engl) 2003; 116:187-90.
4.	Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature 2000; 407:249-57.
5.	Huang GW, Yang LY, Lu WQ. Expression of hypoxia- inducible factor 1α and vascular endothelial growth factor in hepatocellular carcinoma: impact on neovascularization and survival. World J Gastroenterol 2005; 11:1705-8.
6.	Rankkin EB, Giaccia AJ. The role of hypoxia-inducible factors in tumorigenesis. Cell Death Differ 2008; 15: 678- 85.
7.	Rajaganeshan R, Prasad R, Guillou PJ, et al. Expression patterns of hypoxic markers at the invasive margin of colorectal cancers and liver metastases. Eur J Surg Oncol 2009; 35:1286-94.
8.	Houck KA, Ferrara N, Winer J, et al. The vascular endo-thelia growth factor family: identification of a fourth mole- cular species and characterization of alternative splicing of RNA. Mol Endocrinol 1991; 5:1806-14.
9.	Guba M, Von Breitenbuch P, Steinbauer M, et al. Rapa-mycin inhibits primary and metastatic tumor growth by antiangenesis: involvement of vascular endothelial gro- wth factor. Nat Med 2002; 8:128-35.
10	Sergio A, Cristofori C, Cardin R, et al. Transcatheter ar-terial chemoembolization (TACE) in hepatocellular carci-noma (HCC): the role of angiogenesis and invasiveness. Am J Gastroenterol 2008; 103:914-21.
11	Schoenleber SJ, Kurtz DM, Talwalkar JA, et al. Prognostic role of vascular endothelial growth factor in hepatocellular carcinoma: systematic review and meta-analysis. Br J Cancer 2009; 100:1385-92.
12	Liao D, Johnson RS. Hypoxia: a key regulator of angio-genesis in cancer. Cancer Metastasis Rev 2007; 26:281- 90.
13	Pugh CW, Ratcliffe PJ. Regulation of angiogenesis by hypoxia: role of the HIF system. Nat Med 2003; 9:677-84.
14	Jiang BH, Liu LZ. PI3K/PTEN signaling I tumorigenesis and angiogenesis. Biochim Biophys Acta 2008; 1784:150-8.
15	Shim JH, Park JW, Kim JH, et al. Association between increment of serum VEGF level and prognosis after tran-scatheter arterial chemoembolization in hepatocellular carcinoma patients. Cancer Sci 2008; 99:2037-44.
16	Wang W, Xu GL, Jia WD, et al. Expression and correlation of hypoxia inducible factor-1α, vascular endothelial gro- wth factor and microvessel density in experimental rat hepatocarcinogenesis. J Int Med Res 2009; 37:417- 25.

[1]	Li-shan Lian, Yao-guo Yang, Wei Liu, Li-long Guo, Heng Guan, Chang-wei Liu, Yong-jun Li*. Zinc Finger Protein-activating Transcription Factor Up-regulates Vascular Endothelial Growth Factor-A Expression in Vitro△[J]. Chinese Medical Sciences Journal, 2012, 27(3): 171-175.
[2]	Kai Qu, Chang Liu, Qi-fei Wu, Bo Wang, Aasef Mohamed Ali Mansoor, Hao Qin, Qiang Ma, Ya-min Liu. Sclerosing Cholangitis after Transcatheter Arterial Chemoembolization: a Case Report[J]. Chinese Medical Sciences Journal, 2011, 26(3): 190-193.

优先出版

当期目次

过刊浏览

虚拟专题

作者中心

评阅者中心